Contracts

TherImmune Awarded $4.5 Million For HIV Vaccine Development Services

Published in AIDS Weekly, November 5th, 2001

TherImmune Research Corp. has been awarded a three-year $4.5 million HIV Vaccine Development Task Order from the U.S. National Institute of Allergy and Infectious Diseases (NIAID) Indefinite Delivery - Indefinite Quantity Contract (IDIQ). The company will be providing preclinical safety and immunogenicity testing of DNA vaccine candidates for the treatment of HIV.

Based on developments in genomics technology, novel therapeutics, and the increasing need for effective vaccines, TherImmune has made significant investments in establishing unique capabilities in the vaccine development arena. The company is excited to be working with NIAID in this important and...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of AIDS Weekly

Source: AIDS Weekly (2001-11-05)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry